P1003: PERIPHERAL BLOOD CYTOTOXIC T CELLS SHOW EARLY EXHAUSTED FEATURES IN MYELOFIBROSIS PATIENTS

P1003: PERIPHERAL BLOOD CYTOTOXIC T CELLS SHOW EARLY EXHAUSTED FEATURES IN MYELOFIBROSIS PATIENTS

Bibliographic Details
Main Authors:	L. Tavernari, S. Rontauroli, M. Maccaferri, B. Mora, E. Bianchi, S. Parenti, E. Genovese, P. Guglielmelli, C. Carretta, S. Mallia, M. Mirabile, S. Sartini, C. Colasante, L. Potenza, F. Passamonti, E. Tagliafico, M. Luppi, A. M. Vannucchi, R. Manfredini
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846880.96285.fa

Similar Items

P987: A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME
by: E. Genovese, et al.
Published: (2022-06-01)

P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS
by: S. Sartini, et al.
Published: (2022-06-01)

The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
by: Elena Genovese, et al.
Published: (2022-01-01)

P999: ERK1/2 INHIBITION REDUCES OSTEOPONTIN PLASMA LEVELS AND BONE MARROW FIBROSIS IN A MYELOFIBROSIS MOUSE MODEL
by: S. Rontauroli, et al.
Published: (2022-06-01)

P983: SINGLE CELL ANALYSIS ALLOWS THE EARLY DETECTION OF LEUKEMIC CLONES IN MPN PATIENTS
by: C. Carretta, et al.
Published: (2022-06-01)

Increased Plasma Levels of lncRNAs <i>LINC01268</i>, <i>GAS5</i> and <i>MALAT1</i> Correlate with Negative Prognostic Factors in Myelofibrosis
by: Sebastian Fantini, et al.
Published: (2021-09-01)

Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
by: Sandra Parenti, et al.
Published: (2021-02-01)

Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol
by: Chiara Carretta, et al.
Published: (2020-10-01)

Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective
by: Sebastiano Rontauroli, et al.
Published: (2022-12-01)

P1003: RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY.
by: Ciro Rinaldi, et al.
Published: (2023-08-01)

1003. Orobanche rapum-genistae: Orobanchaceae
by: Thorogood, CJ, et al.
Published: (2021)

SH1003 SHARIAH RULES IN FINANCIAL TRANSACTIONS
by: Lahsasna, Ahcene, author 495346
Published: (2012)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
by: Alessandra Carobbio, et al.
Published: (2023-07-01)

Incidence of blast phase in myelofibrosis according to anemia severity
by: Barbara Mora, et al.
Published: (2023-08-01)

Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.
by: Paola Guglielmelli, et al.
Published: (2015-01-01)

Standard care and investigational drugs in the treatment of myelofibrosis
by: Daniela Barraco, et al.
Published: (2019-09-01)

HIP MORPHOLOGY IN A POPULATION BASED COHORT OF 1003 WOMEN
by: Thomas, G, et al.
Published: (2012)

COVID-19: room for treating T cell exhaustion?
by: Giovanni Riva, et al.
Published: (2020-05-01)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
by: Maria Zingariello, et al.
Published: (2020-11-01)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
by: Giacomo Coltro, et al.
Published: (2022-08-01)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
by: Paola Guglielmelli, et al.
Published: (2023-01-01)

Characterization of New <i>ATM</i> Deletion Associated with Hereditary Breast Cancer
by: Sandra Parenti, et al.
Published: (2021-01-01)

Hip morphology in a population based cohort of 1003 women
by: Thomas, G, et al.
Published: (2012)

Intertextuality, interpretation and contextualization of “escarnios” V1003 and B1559
by: Déborah González Martínez
Published: (2012-08-01)

P10.03 ACTIONS OF VERAPAMIL IN PRODUCING VASCULAR RELAXATIONS
by: J.R. Docherty, et al.
Published: (2010-12-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
by: Claire Harrison, et al.
Published: (2022-08-01)

Use of a microprocessor to implement an ADCCP protocol : Federal Standard 1003
by: 253326 Urban, Stephan J.

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
by: F. Passamonti, et al.
Published: (2022-06-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
by: Claire N. Harrison, et al.
Published: (2021-05-01)

Defining disease modification in myelofibrosis in the era of targeted therapy
by: Pemmaraju, N, et al.
Published: (2022)

Guideline for the diagnosis and management of myelofibrosis
by: Reilly, J, et al.
Published: (2012)

Guideline for the diagnosis and management of myelofibrosis.
by: Reilly, J, et al.
Published: (2012)

1003 Hearts or Fragments from a Don Juan Catalogue - Mozgó Ház Társulás
by: Zoltán Imre
Published: (2002-07-01)

P10.03 EVALUATION OF ARTERIAL STIFFNESS IN ATHEROSCLEROTIC RABBITS IN VIVO VIA ECHOTRACKING
by: C. Vayssettes-Courchay, et al.
Published: (2011-11-01)

P10.03 ENDOTHELIUM-SPECIFIC CALCIUM-ACTIVATED POTASSIUM CHANNELS: TARGETS FOR ALDOSTERONE
by: V. Griol-Charhbili, et al.
Published: (2009-12-01)

Focus on Osteosclerotic Progression in Primary Myelofibrosis
by: Mariarita Spampinato, et al.
Published: (2021-01-01)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
by: Tiziano Barbui, et al.
Published: (2022-11-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Possibilities of targeted therapy for myelofibrosis: Moscow experience
by: O. Yu. Vinogradova, et al.
Published: (2022-11-01)